

# One-year consistent safety, utilization, and efficacy assessment of Remote Electrical Neuromodulation (REN) for migraine treatment

**Authors:** Andrea Synowiec<sup>1</sup>, Alit Stark-Inbar<sup>2,\*</sup>, Maya Weinstein<sup>3</sup>, Alon Ironi<sup>2</sup>, Alexander Mauskop<sup>4</sup>

## **Affiliations:**

<sup>1</sup> Allegheny Health Network, Pittsburgh, PA, USA

<sup>2</sup> Theranica Bio-Electronics, Netanya, Israel

<sup>3</sup> The Hebrew University of Jerusalem, Jerusalem, Israel

<sup>4</sup> The New York Headache Center, New York City, NY, USA

\*Corresponding author

## **Emails:**

[Andrea.Synowiec@AHN.org](mailto:Andrea.Synowiec@AHN.org)

[alitsi@theranica.com](mailto:alitsi@theranica.com)

[weinmaya@gmail.com](mailto:weinmaya@gmail.com)

[aloni@theranica.com](mailto:aloni@theranica.com)

[amauskop@gmail.com](mailto:amauskop@gmail.com)

## **Correspondence Details:**

Alit Stark-Inbar, Theranica Bio-Electronics, Netanya, Israel

## **ORCID iDs:**

Andrea Synowiec: 0009-0006-4986-4856

Alit Stark-Inbar: 0000-0001-6434-6447

Maya Weinstein: 0000-0002-3050-6526

Alon Ironi: 0000-0002-3992-4978

Alexander Mauskop: 0000-0002-2861-5184

## **Prior Presentation:**

The manuscript is based, in part, on work presented during the 65<sup>th</sup> Annual Scientific Meeting of the American Headache Society, June 15-18, 2023, Austin, TX.

**Supplementary Material:**

|                 | Pain Relief |       | Pain Freedom |       | Functional Disability Relief |       | Functional Disability Freedom |       |
|-----------------|-------------|-------|--------------|-------|------------------------------|-------|-------------------------------|-------|
|                 | n/N         | %     | n/N          | %     | n/N                          | %     | n/N                           | %     |
| <b>Month 1</b>  | 95/134      | 70.9% | 54/165       | 32.7% | 105/152                      | 69.1% | 64/152                        | 42.1% |
| <b>Month 2</b>  | 93/131      | 71.0% | 50/164       | 30.5% | 91/150                       | 60.7% | 51/150                        | 34.0% |
| <b>Month 3</b>  | 77/115      | 67.0% | 47/145       | 32.4% | 87/131                       | 66.4% | 43/131                        | 32.8% |
| <b>Month 4</b>  | 74/115      | 64.3% | 47/134       | 35.1% | 88/126                       | 69.8% | 48/126                        | 38.1% |
| <b>Month 5</b>  | 65/102      | 63.7% | 40/118       | 33.9% | 74/110                       | 67.3% | 43/110                        | 39.1% |
| <b>Month 6</b>  | 68/98       | 69.4% | 38/118       | 32.2% | 72/110                       | 65.5% | 45/110                        | 40.9% |
| <b>Month 7</b>  | 60/89       | 67.4% | 27/101       | 26.7% | 60/96                        | 62.5% | 34/96                         | 35.4% |
| <b>Month 8</b>  | 56/76       | 73.7% | 31/96        | 32.3% | 58/92                        | 63.0% | 35/92                         | 38.0% |
| <b>Month 9</b>  | 50/71       | 70.4% | 21/84        | 25.0% | 49/75                        | 65.3% | 22/75                         | 29.3% |
| <b>Month 10</b> | 41/64       | 64.1% | 22/79        | 27.8% | 52/73                        | 71.2% | 24/73                         | 32.9% |
| <b>Month 11</b> | 41/58       | 70.7% | 21/70        | 30.0% | 51/66                        | 77.3% | 28/66                         | 42.4% |
| <b>Month 12</b> | 38/52       | 73.1% | 26/64        | 40.6% | 39/57                        | 68.4% | 20/57                         | 35.1% |

**Table S1- Month-to-month one-year efficacy.** Number and percent responders for each of the four headache pain intensity and functional disability efficacy measures (Pain Relief, Pain Freedom, Functional Disability relief, Functional Disability freedom) per month.

|                | Photophobia |       | Phonophobia |       | Nausea/Vomiting |       | Disappearance of at least one associated symptom |       |
|----------------|-------------|-------|-------------|-------|-----------------|-------|--|-------|
|                | n/N         | %     | n/N         | %     | n/N             | %     | n/N  | %     |
| <b>Month 1</b> | 49/114      | 43.0% | 46/98       | 46.9% | 43/62           | 69.4% | 90/135   | 66.7% |
| <b>Month 2</b> | 52/116      | 44.8% | 42/89       | 47.2% | 51/78           | 65.4% | 99/135   | 73.3% |
| <b>Month 3</b> | 40/105      | 38.1% | 45/88       | 51.1% | 49/74           | 66.2% | 83/121   | 68.6% |

|                 |       |       |       |       |       |       |        |       |
|-----------------|-------|-------|-------|-------|-------|-------|--------|-------|
| <b>Month 4</b>  | 35/95 | 36.8% | 41/85 | 48.2% | 42/62 | 67.7% | 69/109 | 63.3% |
| <b>Month 5</b>  | 39/90 | 43.3% | 42/80 | 52.5% | 30/50 | 60.0% | 67/99  | 67.7% |
| <b>Month 6</b>  | 43/87 | 49.4% | 38/75 | 50.7% | 30/50 | 60.0% | 65/98  | 66.3% |
| <b>Month 7</b>  | 40/84 | 47.6% | 35/69 | 50.7% | 34/53 | 64.2% | 66/90  | 73.3% |
| <b>Month 8</b>  | 32/74 | 43.2% | 34/61 | 55.7% | 29/44 | 65.9% | 57/79  | 72.2% |
| <b>Month 9</b>  | 23/63 | 36.5% | 27/56 | 48.2% | 22/41 | 53.7% | 43/72  | 59.7% |
| <b>Month 10</b> | 29/66 | 43.9% | 24/47 | 51.1% | 20/35 | 57.1% | 47/69  | 68.1% |
| <b>Month 11</b> | 26/56 | 46.4% | 19/39 | 48.7% | 23/30 | 76.7% | 48/63  | 76.2% |
| <b>Month 12</b> | 21/46 | 45.7% | 16/32 | 50.0% | 21/29 | 72.4% | 36/49  | 73.5% |

**Table S2- Month-to-month one-year efficacy of associated symptoms.** Number and percent responders for each of the four associated symptoms efficacy measures reflecting the disappearance of the associated symptom 2 hours post-treatment (photophobia, phonophobia, nausea/vomiting, at least one of the associated symptoms) per month.